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Background: Visceral leishmaniasis caused by the protozoan parasite Leishmania donovani complex is a potentially
fatal disease if left untreated. Few treatment options exist and are toxic, costly and ineffective against resistant
strains. Thus a safe and efficacious vaccine to combat this disease is needed. Previously, we reported that intraperitoneal
administration of leishmanial antigens (LAg) entrapped in liposomes conferred protection to BALB/c mice against
L. donovani challenge infection. However, this vaccine failed to protect mice when administered subcutaneously. We
therefore evaluated whether formulation of LAg in combination with two commonly used human-compatible
adjuvants, alum and saponin, could improve the protective efficacy of subcutaneously administered LAg, to a level
comparable to that of the intraperitoneal liposomal vaccination.
Results: Vaccine formulations of LAg with alum or saponin failed to reduce parasite burden in the liver, and alum +
LAg immunized mice also failed to reduce parasite burden in the spleen. Interestingly, saponin + LAg vaccination
actually resulted in an increased L. donovani parasitic load in the spleen following L. donovani challenge, suggesting this
regimen exacerbates the infection. In contrast, mice immunized intraperitoneally with Lip + LAg demonstrated
significant protection in both liver and spleen, as expected. Mechanistically, we found that failure of alum + LAg to
protect mice was associated with elevated levels of IL-4, whereas both IL-4 and IL-10 levels were increased in saponin +
LAg immunized mice. This outcome served to exacerbate L. donovani infection in the saponin + LAg group, despite a
concurrent increase in proinflammatory IFN-γ production. On the contrary, protection against L. donovani challenge in
Lip + LAg immunized mice was associated with elevated levels of IFN-γ in conjunction with low levels of IL-4 and IL-10
production.
Conclusions: These findings indicate that elevated levels of IL-4 may contribute to LAg vaccine failure, whereas
combined elevation of IL-4 together with IL-10 exacerbated the disease as observed in saponin + LAg immunized mice.
In contrast, a robust IFN-γ response, in the absence of IL-4 and IL-10 production, was associated with protective
immunity following administration of the Lip + LAg vaccine. Together these findings suggest that optimization of
antigen/adjuvant formulations to minimize IL-4 and IL-10 induction may be helpful in the development of high efficacy
vaccines targeting Leishmania.
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Leishmaniasis is an important global public health prob-
lem with an estimated 350 million people at risk of in-
fection. The disease is caused by parasites of the genus
Leishmania and can be classified into three major forms
based on their clinical manifestations. Whilst cutaneous
leishmaniasis (CL) and mucocutaneous leishmaniasis
(MCL) represent milder forms of the disease, visceral
leishmaniasis (VL) is associated with a high mortality
rate [1]. Currently, the available antileishmanial drugs
are costly, toxic, induce severe side effects, and are inef-
fective against emerging drug resistant Leishmania
strains. Therefore, the study and development of add-
itional safe and effective vaccine regimens for clinical
use remains critical.
The production of vaccines to combat leishmaniasis is
increasingly reliant on subunit antigen constructs. Whilst
defined antigens offer advantages in terms of safety, they
are typically less immunogenic and require the addition of
an adjuvant to be effective [2,3]. In our attempt to design
a vaccine against VL we initiated studies with antigens of
Leishmania donovani promastigotes (LAg) in association
with liposomes as a vaccine delivery vehicle, as well as an
adjuvant. Entrapment of LAg in liposomes led to remark-
able levels of protection against L. donovani infection in
hamsters and BALB/c mice when administered through
the intraperitoneal route [4,5]. However, immunization via
the subcutaneous route with the same liposomal vaccine
failed to elicit protection [6]. This low efficacy following
subcutaneous injection represents a critical barrier that
currently limits the clinical applicability of a liposomal
LAg subunit vaccine.
Whilst many adjuvants which are routinely used in la-
boratory animals are often incompatible for human use,
alum has been licensed for human vaccines for decades
and is still widely incorporated into new vaccine formu-
lations currently in development [7]. In relation to leish-
maniasis, alum has been used in combination with IL-12
and killed promastigotes, resulting in effective protection
in a primate model of CL [8]. Furthermore, an alum-
absorbed preparation of autoclaved L. major (alum-ALM)
mixed with Bacillus Calmette-Guerin (BCG) protected
Langur monkeys against VL [9]. Indeed, alum-ALM was
found to be tolerable in healthy volunteers, whilst impart-
ing minimal side-effects and conferring improved im-
munogenicity compared to preparations lacking the alum
component [10]. These observations led to the use of this
vaccine as an immunological stimulus for the treatment
of patients with persistent post kala-azar dermal leish-
maniasis (PKDL), where vaccine administration was
shown to significantly improve the clinical outcome of
PKDL lesions [11].
Saponin consists of natural glycosides of steroid or tri-
terpene, which can activate the mammalian immunesystem, leading to significant interest in developing sap-
onin as a vaccine adjuvant. Saponin has already been in-
cluded as an adjuvant in clinical vaccine formulations
against HIV and cancer [12]. Combined administration
of saponin and fucose manose ligand (FML) antigen
from L. donovani was additionally found to be protective
against VL in both mice and dogs [13,14], and moreover
the FML-vaccine was also effective in an immunothera-
peutic context against the same disease [15,16]. Similarly
the Leishmune® vaccine, composed of FML antigen with
an increased concentration of saponin exhibited immuno-
therapeutic potential in dogs, reducing clinical symptoms
following L. chagasi challenge [17]. There is therefore
much hope for a saponin-adjuvanted leishmanial vaccine
in veterinary and clinical research.
Alum and saponin are both approved for human use
and have been widely applied in numerous clinical
vaccine trials [7,12]. Therefore, in the present study we
investigated the protective efficacy of LAg against L.
donovani challenge in isolation, or in combination with
either alum or saponin adjuvants administered through
a subcutaneous route, as compared to the highly effica-
cious intraperitoneal route of lip + LAg administration
in BALB/c mice.
Results
LAg immunization in combination with alum or saponin
fails to reduce parasite burden, whereas a lip + LAg
vaccine regimen induces protective immunity in the liver
To determine the protective efficacy of LAg formulated
in alum, saponin or liposomes, cohorts of naive BALB/c
mice underwent a prime-boost immunization regimen
with subcutaneously administered alum + LAg or sap-
onin + LAg. As control, mice were administered with
lip + LAg vaccine intraperitoneally, whereas negative
control mice received PBS or adjuvant alone (subcutane-
ously). Mice were then challenged with L. donovani pro-
mastigotes 10 days after vaccination. Inoculation of
BALB/c mice with L. donovani strain AG83 leads to pro-
gressive infection in the liver and spleen, corresponding
with hepato- and splenomegaly [4,18]. We therefore eval-
uated the kinetics of increasing parasitic burden at 2 and 4
months after challenge, and the parasite loads in liver and
spleen were quantitated as Leishman Donovan Units
(Figure 1).
In the liver, we observed a trend of decreased parasitic
load in both alum + LAg and saponin + LAg immunized
mice as compared to PBS immunized control group,
reaching statistical significance at 2 months postinfection
(p < 0.05, Figure 1A). However, this effect was minor, and
notably neither vaccine statistically improved the protect-
ive efficacy over immunization with adjuvant alone. Mice
immunized with LAg alone also did not exhibit sig-
nificantly reduced parasite load compared to controls,
Figure 1 Parasite burdens in vaccinated mice after L. donovani challenge infection. BALB/c mice were vaccinated subcutaneously with PBS,
LAg, alum, alum + LAg, saponin and saponin + LAg, or intraperitoneally with Lip and Lip + LAg. Ten days post-immunization, mice were
challenged intravenously with 2.5 × 107 promastigotes of L. donovani. Liver (A) and spleen (B) parasite burden was measured 2 and 4 months
after challenge, and expressed as Leishman Donovan Units. Bars represent the mean ± SE of five individual mice per group, representative of two
independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 in comparison to PBS as well as free adjuvant immunized groups as assessed by a
one-way ANOVA and Tukey’s multiple comparison test.
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ministered subcutaneously did not influence parasite
growth in the liver [6]. In contrast, significantly reduced
parasite burden was seen following intraperitoneal immu-
nization with lip + LAg as compared to both PBS and
empty liposome immunized mice (p < 0.001) [4,6]. At 4
months postinfection both alum + LAg and saponin +
LAg immunized mice failed to maintain the slight reduc-
tion in the parasite levels seen at the 2 month time point,
instead demonstrating infection levels comparable to PBS
and free adjuvant-immunized controls. In contrast, lip +
LAg immunized animals maintained lower levels of para-
site burden versus controls (p < 0.001).
Immunization with alum + LAg fails to reduce splenic
L. donovani burden whereas immunization with saponin +
LAg exacerbates infection
In VL, the spleen acts as a reservoir for parasitic persist-
ence, which is further associated with induction of host
tolerance, and failure to clear the disease [4,5,18]. We
therefore wished to monitor the effect of immunization
with different LAg vaccine formulations on the splenic
persistence of L. donovani following challenge. At 2
months postinfection, alum + LAg and saponin + LAg
immunized cohorts both failed to control L. donovani
infection in spleen, exhibiting parasite burden com-
parable to PBS and free adjuvant-immunized controls
(Figure 1B). Failure to protect against infection in mice
immunized with alum + LAg was also observed 4 months
after infection. Contrary to our expectations, we observed
significantly increased parasite burden in the spleen of
mice immunized with saponin + LAg at the 4 month time
point (p < 0.05) indicating this vaccine regimen exacer-
bated infection. In opposition, lip + LAg immunized
mice showed a significant reduction in splenic parasiteburden at 4 months post infection (p < 0.001 in compari-
son to PBS and free adjuvant-immunized controls), as
expected [4].
Induction of humoral response in immunized mice
VL is characterized by polyclonal antibody response,
which helps to establish and maintain infection [19] and
may even lead to disease exacerbation [20]. Thus it was
of interest to investigate whether a specific/nonspecific
antibody response plays a role in dictating vaccine effi-
cacy. Sera were collected from immunized mice before
L. donovani challenge, after 2 and 4 months of infection
and assayed for LAg specific total IgG, and its isotypes
IgG1, IgG2a and IgG2b. At 10 days post-vaccination,
mice immunized with alum + LAg, saponin + LAg and
lip + LAg induced significantly higher levels of LAg-
specific IgG, and its isotypes IgG1, IgG2a and IgG2b in
comparison to PBS as well as free adjuvant-immunized
controls (Figure 2A, p < 0.05). IgG2a and IgG1 are surro-
gate markers for Th1 and Th2 responses, respectively
[21], and both lip + LAg (1.40) and saponin + LAg (1.2)
immunized mice showed a high IgG2a:IgG1 ratio that
was suggestive of a Th1 bias, whereas the IgG2a:IgG1 ra-
tio in alum + LAg immunized mice (0.90) revealed a
skewing towards Th2 (Figure 2D). As control for the
specificity of the response, serum antibody levels to a
nonleishmanial antigen OVA were also assessed, and we
observed minimal reactivity in all experimental condi-
tions at 10 days post-vaccination (Figure 2A, inset).
After 2 months post- L. donovani infection, the levels
of IgG increased further in alum + LAg and saponin +
LAg immunized mice, differing significantly from con-
trols (Figure 2B, p < 0.01). Although the levels of IgG1
and IgG2b were comparable to the infected control
mice, significantly higher levels of IgG2a (p < 0.05) were
Figure 2 Humoral response in vaccinated mice following immunization and L. donovani challenge infection. Mice were immunized
subcutaneously with PBS, LAg, alum, alum + LAg, saponin, saponin + LAg, or intraperitoneally with Lip and Lip + LAg. ELISA measurement of
LAg-specific IgG, IgG1, IgG2a and IgG2b antibodies was performed on sera obtained from mice post-immunization (A), 2 months (B) and
4 months (C) after challenge with L. donovani. The insets in (A) and (C) show antibody levels to the non-leishmanial control antigen OVA. Each
sample was examined in duplicate. The results are shown as the mean absorbance values ± SE of five individual mice per group, representative of
two independent experiments with similar results. IgG2a/IgG1 ratio in alum + LAg, saponin + LAg and Lip + LAg immunized mice (D) preinfection,
2 months and 4 months postinfection (pi). * p < 0.05, ** p < 0.01, *** p < 0.001 in comparison to PBS as well as free adjuvant immunized groups as
assessed by one-way ANOVA and Tukey’s multiple comparison test.
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protection observed in liver at 2 months postinfection.
Interestingly, the IgG2a:IgG1 ratios of alum + LAg (0.96)
and saponin + LAg (1.24) observed at 2 months post-
infection maintained a bias towards Th2 and Th1 respect-
ively, in keeping with our observations from sera obtained
prior to L. donovani challenge. In contrast, mice vacci-
nated with lip + LAg exhibited higher levels of IgG2a and
IgG2b, and a higher IgG2a:IgG1 ratio (1.47) than controls,
strongly indicative of Th1 skewing.
With progressive infection at 4 months, both nonspe-
cific and LAg-specific IgG levels were elevated in all
groups including the PBS vaccinated and free-LAg vacci-
nated controls, however there was no significant differ-
ence in the nonspecific response within the LAg +
adjuvanted groups (Figure 2C, inset). Moreover, we didobserve that alum + LAg immunized mice showed higher
levels of LAg-specific IgG1 (p < 0.05) and comparable
levels of IgG2a to controls, culminating in a lower IgG2a:
IgG1 ratio (0.8) (Figure 2C). Saponin + LAg immunization
induced a trend of elevated IgG1 and IgG2a but the levels
were not significantly different from the controls. How-
ever, saponin + LAg immunized mice nevertheless exhib-
ited a high IgG2a:IgG1 ratio (1.12) reflecting stimulation
of a Th1 biased immune response. In lip + LAg immu-
nized mice the levels of IgG2a and IgG2b were again
higher (p < 0.05) in comparison to both PBS and free
adjuvant-immunized controls and showed a strong Th1
bias with a high IgG2a:IgG1 ratio (1.64), in keeping with
the trend seen in this group post-vaccination.
The results thus demonstrate that although a non-
specific polyclonal antibody response is induced by
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sponse influences the failure of protection or exacerba-
tion of infection in alum + LAg or saponin + LAg
conditions respectively. In contrast, higher levels of
LAg-specific IgG1 and comparable levels of IgG2a in
alum + LAg immunized mice indicated a Th2 bias, and
correlated with an observed failure of protection in these
animals. Although an inability to maintain high levels of
IgG2a was observed in saponin + LAg immunized mice,
the ratio of IgG2a:IgG1 nonetheless suggests a Th1 bias
is extant post-immunization, that could be maintained 2
and 4 months post-infection. However, mice in this
group not only failed to show protection in liver, but
also exhibited exacerbation of infection in spleen. Only
mice immunized with lip + LAg, showing elevated levels
of both IgG2a and IgG2b, and exhibiting a high IgG2a:
IgG1 ratio indicative of a strong Th1 bias, were pro-
tected during L. donovani challenge.
Delayed type hypersensitivity (DTH) responses correlate
with failure of protection but do not explain exacerbation
of infection in immunized mice
To evaluate cell-mediated immune responses to LAg fol-
lowing vaccination, we monitored delayed-type hypersen-
sitivity (DTH) responses in mice 10 days post-vaccination
and 2 and 4 months post L. donovani challenge infection.
Vaccination of mice with LAg in association with alum,
saponin and liposomes all increased the DTH response
(Figure 3, p < 0.05 in comparison to PBS as well as freeFigure 3 DTH responses in vaccinated mice following
immunization and L. donovani challenge infection. LAg-specific
DTH responses were measured ten days post-vaccination, or 2 and
4 months after challenge infection. DTH response is expressed as
the difference (in millimeters) between the thickness of the test
(LAg-injected) and control (PBS-injected) footpads at 24 h. Bars
represent the mean ± SE of five individual mice per group, and are
representative of two independent experiments. * p < 0.05, ** p <
0.01, *** p < 0.001 in comparison to PBS as well as free adjuvant
immunized groups as assessed by one-way ANOVA and Tukey’s
multiple comparison test.adjuvant-immunized controls), and in addition at 2 months
post- L. donovani challenge the response was further ele-
vated in all of the vaccinated groups. The highest DTH re-
sponse correlated well with the protection in lip + LAg
immunized mice. We observed a partial reduction in para-
site burden in liver after 2 months in alum + LAg and sap-
onin + LAg immunized groups (Figure 1), which also
correlated with high DTH responses induced in these ani-
mals (p < 0.01 in comparison to PBS as well as free
adjuvant-immunized controls). However, at 4 months of
infection mice immunized with alum + LAg and saponin +
LAg showed minimal differences in DTH response as
compared with PBS as well as free adjuvant-immunized
controls. In contrast, lip + LAg immunized mice main-
tained elevated DTH responses significantly higher than
controls (p < 0.05). The ability to sustain DTH responses at
4 months postinfection can be correlated with the ability
of lip + LAg, but not alum + LAg or saponin + LAg vacci-
nated groups to protect against L. donovani challenge
infection. However, we found no evidence that the DTH
responses could explain the exacerbation of L. donovani
infection observed in spleen of mice immunized with sap-
onin + LAg observed at 4 months.
Cytokine response in LAg + adjuvant immunized mice is
a correlate of the clinical outcome following L. donovani
challenge
Neither the humoral polyclonal antibody response nor
the cell-mediated DTH response could entirely explain
the observed disease progression in LAg + adjuvant im-
munized mice following challenge with L. donovani. We
therefore asked whether LAg specific recall cytokine re-
sponses could provide use with a further mechanistic
insight. To do so, we cultured splenocytes from experi-
mental cohorts 10 days post-immunization, and 4
months after L. donovani challenge infection. Spleno-
cytes from mice vaccinated with alum + LAg secreted
significantly higher levels of IL-12 in comparison to free
adjuvant-immunized controls (Figure 4A, p < 0.05). In
addition, IFN-γ measured in splenocyte cultures was
also significantly higher compared to both PBS and free
adjuvant-immunized controls (Figure 4C, p < 0.05). We
performed blocking experiments with anti-CD4 and
anti-CD8 monoclonal antibodies to assess the relative
contributions of CD4+ and CD8+ T cells to this cytokine
production, revealing that IFN-γ secretion in alum +
LAg immunized mice was produced mainly from CD8+
T cells, whereas CD4+ T-cell blocking had only a negli-
gible effect. In contrast, the levels of IL-4 produced by
CD4+ T cells was significantly higher not only in com-
parison to controls (Figure 4E, p < 0.001), but also to
other remaining groups (p < 0.05). A low IFN-γ:IL-4 ra-
tio (0.8) was observed in the alum + LAg vaccinated
group and furthermore significant IL-10 production was
Figure 4 Cytokine response in vaccinated mice following immunization and L. donovani challenge infection. Ten days post-vaccination
and 4 months after L. donovani challenge infection splenocytes were restimulated in vitro with LAg (10 μg/mL) in media alone or in the presence
of anti-CD4 or anti-CD8 monoclonal antibody (1 μg/106 cells). After 72 h supernatants were collected and assayed for IL-12 ((A, B), IFN-γ (C, D),
IL-4 (E, F) and IL-10 (G, H)) by ELISA. Each sample was examined in duplicate. The results are shown as the mean ± SE for five individual mice per
group, representative of two independent experiments with similar results. * p < 0.05, ** p < 0.01, *** p < 0.001 in comparison to PBS as well as
free adjuvant immunized groups as assessed by one-way ANOVA and Tukey’s multiple comparison test.
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free adjuvant-immunized controls (Figure 4G).
In contrast, splenocytes from saponin + LAg immu-
nized mice produced significantly higher levels of IL-12
and IFN-γ in comparison controls (Figure 4A, C; p <
0.001). Notably, elevated levels of IL-4 and IL-10 were
also produced by splenocytes of the saponin + LAg
group (p < 0.001 compared to controls). Production of
both IL-4 and IL-10 was substantially inhibited by
addition of anti-CD4 blocking antibody to cultures, indi-
cating that both of these cytokines were likely produced
by the CD4+ T cell subset (Figure 4E, G). Despite exhi-
biting higher IL-4 and IL-10 levels following immuniza-
tion, saponin + LAg immunized animals still exhibited
high IFN-γ:IL-4 (1.59) and IFN-γ:IL-10 (1.60) ratios, per-
haps demonstrating a subtle Th1 bias.
Finally, splenocytes from mice immunized with lip +
LAg secreted higher levels of IL-12 and IFN-γ from both
CD4+ and CD8+ T cells, in comparison to those immu-
nized with PBS as well as free adjuvant immunized
control groups (p < 0.01). Lip + LAg immunized mice
additionally exhibited low although still statistically signifi-
cant IL-4 production, secreted mainly from CD4+ T cells
(p < 0.05 compared to controls), whereas IL-10 production
was not observed in this group, above background.
We asked whether early cytokine production was indi-
cative of subsequent outcome following L. donovani in-
fection. Four months after L. donovani challenge, low
levels of IL-12 (Figure 4B) and IFN-γ (Figure 4D) with
elevated levels of IL-4 (Figure 4F) and IL-10 (Figure 4H)
were observed in the culture supernatants of splenocytes
of PBS and free adjuvant vaccinated control animals, as
reported previously [6]. In alum + LAg immunized mice
the level of IFN-γ, secreted mainly from CD8+ T cells,
was elevated (p < 0.01 compared to both PBS and free
adjuvant-immunized control groups). Although IL-10
levels remained comparable to controls, the levels of IL-4
produced in alum + LAg immunized mice were signifi-
cantly enhanced at 4 months post-challenge infection (p <
0.001). Moreover, the IFN-γ:IL-4 ratio (0.74) remained
low suggesting a Th2 bias in this condition.
In saponin + LAg vaccinated mice, we were surprised
that IFN-γ secreted from both CD4+ and CD8+ T cells
actually increased post-infection (p < 0.001 compared to
controls), despite the failure of this vaccine regimen to
induce protection. Moreover, the levels of IFN-γ mea-
sured in the splenocyte culture supernatants remained
higher in comparison to alum + LAg immunized mice
(p < 0.01). However, notably the CD4+ T cell derived IL-
4 and IL-10 production was also significantly increased
following saponin + LAg vaccination, showing elevation
over both PBS as well as free adjuvant-immunized con-
trol groups controls (p < 0.01). Although a high IFN-γ:
IL-4 ratio (1.34) was observed demonstrating Th1 bias, alow IFN-γ:IL-10 ratio (0.6) was found to correlate with
the exacerbation of infection in spleen observed follow-
ing L. donovani challenge (Figure 1).
Splenocytes of mice immunized with Lip + LAg showed
enhanced production of IL-12 and IFN-γ at 4 months
(p < 0.01) in comparison to controls, and our experi-
ments showed that IFN-γ production occurred from
both CD4+ and CD8+ cells (Figure 4B, D). Low levels of
IL-4 and IL-10 secreted from CD4+ T cells were ob-
served (p < 0.01 in comparison to controls) with a high
IFN-γ:IL-4 (5.69) and IFN-γ:IL-10 (4.6) ratio also seen in
this group (Figure 4F, H). The ratio implicated that a
strong Th1 bias may be an important correlate of pro-
tection within this group.
In sum, we found that high IFN-γ and IL-12 produc-
tion correlated with protective immunity following ad-
ministration of a lip + LAg vaccine regimen. In contrast,
despite the presence of elevated IFN-γ, the concurrent
upregulation of IL-4 in alum + LAg immunized mice ap-
parently overrode any protective effect exerted by IFN-γ,
and correlated with failure of protection. Furthermore,
high levels of both IL-4 and IL-10 correlated with ex-
acerbation of disease in L. donovani challenged mice that
had been vaccinated with saponin + LAg. These results
clarify the differential immunological effects exerted by al-
ternative adjuvants formulated with the LAg antigen and
delivered subcutaneously.
Discussion
Despite the fact that the majority of vaccines licensed
for clinical use against VL remain live, attenuated, or
killed crude preparations [2,3], much effort has been de-
voted to identify new Leishmania subunit/adjuvant com-
binations that are clinically efficacious. However, there
are only few suitable adjuvants that have been licensed
for human and veterinary vaccine use. Thus, a successful
anti-leishmanial subunit vaccine will need to be assessed
with human-compatible adjuvants. In our laboratory we
have identified LAg as a potential candidate antigen,
which was efficacious when associated with liposomes and
vaccinated intraperitonealy in mice and hamsters [4,5].
However, In contrast to other reports utilizing differential
liposomal formulations and administered subcutaneously
[22,23], comparative evaluation of intraperitoneal and
subcutaneous vaccination with LAg entrapped in our lipo-
somal composition failed to protect against challenge
infection through subcutaneous route [6]. Alum remains
the most widely used adjuvant in human vaccines, and
saponin is one of the promising adjuvant that has more
recently been licensed for human use [7,12]. To facili-
tate broad clinical applicability, the preferred route of
delivery is the minimally invasive subcutaneous route.
Thus in an attempt to overcome the failure of subcuta-
neous vaccination with LAg in liposomes, this study
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with two widely used human-compatible adjuvants when
injected subcutaneously.
Alum has been conventionally used as a clinical adju-
vant for a wide range of vaccines that target a humoral
immune response. However, the use of alum as an adju-
vant for vaccination against the intracellular pathogen
Leishmania has also been tested previously. In L. major,
a vaccine containing killed parasites and IL-12 adjuvant
was found to be prophylactically ineffective [24], how-
ever this antigen along with alum and IL-12 did induce
protection in primates [8]. Moreover, encouraging re-
sults following vaccination in a primate model with
combinations of alum-precipitated ALM and either BCG
[9] or IL-12 [8] formed the basis of a human trial for a
potential vaccine against VL. Safety and immunogenicity
studies conducted under field conditions including
healthy volunteers [10], as well as children who are at
high risk of VL [25], indicated that the vaccine contain-
ing alum-precipitated ALM with BCG was safe and well
tolerated. Again, the observation that the vaccine was
highly immunogenic and could induce a strong Th1 re-
sponse [10,26] led to the use of the formulation as an
immunological stimulus for the successful treatment of
patients with persistent PKDL [11]. Despite these satis-
factory results, to our knowledge, such a formulation
has not been examined for its efficacy in trials against
VL. Herein we observed that alum + LAg failed to pro-
tect BALB/c mice against challenge with L. donovani.
We therefore envisage that inclusion of a second Th1
promoting adjuvant such as IL-12 or BCG with alum
will be necessary for an alum containing vaccine to be
clinically successful against both CL and VL [8,9]. None-
theless, it must be considered that failure of alum-ALM +
BCG to protect susceptible BALB/c against L. major [27]
raises some concern about the similar use of such an adju-
vant in humans.
Saponin remains the immunopotentiator of choice in
many cancer and infectious disease vaccine trials, such
as malaria, HIV, hepatitis and tuberculosis [12]. In ex-
perimental VL FML or the immunodominant leishman-
ial antigen (NH36) formulated with saponin was found
to be effective when administered prophylactically
[13,28], and furthermore such formulations were also
found to be efficacious when utilized immunotherapeuti-
cally [14,16]. These results facilitated the development of
the currently licensed vaccine Leishmune®, composed of
FML with increased amounts of saponin for field trials
against canine VL. Indeed, Leishmune® has been recently
shown immunotherapeutic potential for vaccination
against canine VL [17]. In contrast to these reports, our
study showed that saponin + LAg immunization not only
failed to reduce parasite burden in liver of L. donovani
challenged mice but also caused exacerbation of infectionin spleen. These findings are partly in keeping with those
of Grenfell et al., who observed that antigenic extracts of
L. amazonensis or L. braziliensis in association with sap-
onin conferred only partial protection against L. chagasi
[29]. Thus, the efficacy of saponin with leishmanial anti-
gens other than FML may vary, and such observations
warrant further pre-clinical studies to establish the poten-
tial of saponin to adjuvant vaccines against leishmaniasis.
Hypergammaglobulinemia and non-specific polyclonal
antibody responses are hallmarks of VL. However,
vaccine-induced antigen specific humoral response and
their isotype profiles are often used as convenient surro-
gate markers of Th1 and Th2 response [21]. Evidence
from both human patients and mice indicate that B-cell
activation and production of polyclonal IgG may con-
tribute to disease pathogenesis, leading to exacerbation
of disease [19,20]. The absence of a detectable non-
specific IgG response in mice immunized with alum +
LAg and saponin + LAg suggests that polyclonal anti-
body responses do not contribute to the failure of pro-
tection in our system. Conversely, isotypic analysis
revealed high levels of IgG1, IgG2a and IgG2b in both
groups and demonstrate a mixed Th1/Th2 response.
With infection the alum + LAg group failed to maintain
the levels of IgG2a and IgG2b but nonetheless exhibited
elevation of IgG1, reflecting a dominance of Th2, which
correlates with the failure of protection in this group. In
contrast, saponin + LAg immunized mice showed levels
of IgG2a, IgG2b and IgG1 comparable with controls.
Nevertheless, an increased IgG2a:IgG1 in the saponin +
LAg condition is suggestive of a subtle Th1 bias, but it
remains unclear how this may relate to the exacerbation
of challenge infection in the spleen. Mice immunized
with lip + LAg induced high levels of both IgG2a and
IgG2b revealing that strong Th1 dominance is a correl-
ate of protection in this group.
In an effort to further define the mechanism/s under-
lying protection induced by intraperitoneal lip + LAg ver-
sus the inability of subcutaneous immunization with
alum + LAg or saponin + LAg to induce protection, we
finally analyzed cytokine production by vaccinated co-
horts in response to re-stimulation with LAg in vitro.
Analysis of cytokines from splenocytes ex vivo revealed
that animals vaccinated with lip + LAg produced high
levels of both IL-12 and IFN-γ. Specifically we found that
CD4+ and CD8+ T cells both contributed to this cytokine
production, and may play an essential role in inducing re-
sistance versus L. donovani [5,6,18]. Immunization with
lip + LAg also enhanced the production of IL-4 and thus
substantiated earlier observations from our lab and others
suggesting that low levels of IL-4 at early time points are
not detrimental and may even be beneficial in promoting
Th1 differentiation, both maintaining IFN-γ production
and priming IL-12 production in VL [5,18,30-32].
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low but nevertheless detectable levels of IFN-γ derived
mainly from CD8+ T cells, whereas we also observed a ro-
bust IL-4 response from CD4+ T cells in these conditions.
It is well established that alum promotes Th2 responses
[7], but recently Serre et al. found that alum-precipitated
proteins can also induce CD8+ T cells to produce Th1-
associated IFN-γ [33]. In L. major, susceptibility to infec-
tion is related with the Th1/Th2 balance, and in particular
IL-4 expression has been implicated as playing a role. Pro-
tective efficacy of vaccine formulations in CL is related
not only with induction of Th1 responses but also the pre-
vention of a Th2 response. Th2 responses have been sug-
gested to override and thus abrogate even a strong Th1
effector function [34]. The higher levels of IL-4 induced
by alum + LAg immunization in comparison to other
vaccinated groups may therefore hinder the protective
efficacy in this group. Thus, the failure of protection in
alum + LAg immunized mice may be a direct result of the
strong IL-4-driven Th2 response that predominated.
Interestingly, we observed that saponin + LAg immu-
nized mice produced high levels of IL-12 and IFN-γ from
both CD4+ and CD8+ T cells suggesting an overriding
Th1-skewed response in this group. Such effects were also
paralleled with significantly elevated Th2 cytokine pro-
duction, namely IL-4 and IL-10, that was predominantly
CD4+ T cell dependent. Several authors have shown an
ability of saponin to upregulate the production of IFN-γ
[12,13,28]. However, to our knowledge, our report repre-
sents the first observation that a saponin adjuvanted vac-
cine can induce robust IL-4. On the contrary, Greenfell
et al., reported that vaccination with antigenic extracts of
L. braziliensis and L. amazonensis associated with saponin
resulted in reduced production of IL-4 [29]. There are few
reports of low levels of IL-10 production [35] and a low
ratio of IFN-γ/IL-10 producing T cells [28] with vaccin-
ation of FML antigen or its component formulated with
saponin in mice. However, most of the studies with these
formulations have not been investigated for the stimula-
tion of IL-10 production. In contrast, strong IL-10 as well
as IL-4 responses was observed following immunization
of Trypanosoma cruzi lysate adjuvanted with saponin [36].
Studies in humans [37], in mice with genetic ablation of
IL-10 [38], or in conjunction with IL-10 receptor blockade
[39], established that IL-10 is the major immunosuppres-
sive cytokine in VL. The generalized negative regulatory
role of IL-10 in vaccine failure is indeed well established
[40]. Interestingly, exacerbation of L. major infection was
associated with higher levels of both IL-4 and IL-10 rela-
tive to IFN-γ [41]. Consistent with this study, our results
suggest that IL-10 is a major determinant of L. donovani
disease progression in saponin + LAg vaccinated mice,
and moreover IL-10 may collude with IL-4, to override
the proinflammatory functions of IFN-γ.L. donovani infection is characterized by distinct organ-
specific pathogen/immune interactions, whereby the liver
is the site of infectious resolution, whereas the spleen
represents the site of parasitic persistence. In the liver,
IFN-γ produced by both NK cells and T cells functions to
resolve L. donovani infection [42]. In keeping with these
findings, saponin + LAg immunized mice induced robust
IFN-γ leading to specific protection in the liver at an
early stage of infection (2 months). Infection models have
produced unequivocal evidence that IL-10 is responsible
for pathogen persistence [42,43] and thus, neutralization
of IL-10 resulted in more effective clearance of Leish-
mania from the splenic compartment [44]. Thus, simul-
taneous production of high IL-4 and IL-10 may be the
mechanistic determinant of the exacerbated infection ob-
served in the spleen of saponin + LAg immunized mice.
Taken together, our study highlights the difficulties
underlying the search for a highly efficacious leishmanial
subunit vaccine in a clinical setting. The results herein sup-
port a model whereby efficacious subcutaneous vaccine
formulations will be predicted to target both robust IFN-γ
production and a strong Th1 response, but must minimally
induce the immunosuppressive cytokines IL-4 and IL-10.
Conclusions
Our data show that vaccination with alum + LAg and sap-
onin + LAg failed to reduce hepatic parasite burden in
BALB/c mice. Moreover, whereas alum + LAg immuniza-
tion also led to vaccine failure as evidenced in the splenic
compartment, saponin + LAg immunization actually re-
sulted in exacerbation of L. donovani infection in this
organ. A high IL-4 response coinciding with enhanced
IgG1 correlated with a failure of protection in alum + LAg
immunized mice, whereas exacerbation of infection in
saponin + LAg immunized mice may involve the unbal-
anced secretion of IL-4 in conjunction with IL-10.
Critically, these results highlight that a limitation to
administer LAg through the subcutaneous route cannot
be overcome with the use of the human-compatible ad-
juvants alum or saponin, tested herein. Moreover, vac-
cines targeting Leishmania, should aim to generate
robust IFN-γ, whilst preventing unfavourable increases
of immunosuppressive cytokines including IL-4 and IL-
10. We suggest that further detailed examination of the
immunoregulatory responses governing IFN-γ, IL-4 and
IL-10 production in immunized mice will greatly focus a
priori design considerations necessary to speed produc-
tion of novel leishmanial vaccines.
Methods
Animals
BALB/c mice were bred in the animal facility of Indian In-
stitute of Chemical Biology Kolkata, India, and were be-
tween 4–6 weeks of age at the onset of the experiments.
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mittee for the Purpose of Control and Supervision on Ex-
perimental Animals (CPCSEA), Ministry of Environment
and Forest, Govt. of India, and approved by the animal
ethics committee (147/1999/CPSCEA) of Indian Institute
of Chemical Biology.
Parasite culture
L. donovani strain AG83 (MHOM/IN/1983/AG83) was
maintained by serial passage in hamsters and BALB/c
mice as described elsewhere [4]. Promastigotes were
grown and subcultured at 22°C in Medium 199 (pH 7.4)
supplemented with 20% heat inactivated fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin,
25 mM HEPES, 100 μg/ml streptomycin sulphate (all
from Sigma-Aldrich, St. Louis, MO, USA). Subcultures
were undertaken at an average density of 2 × 106 cells/mL.
Preparation of LAg and adjuvants
LAg was prepared from L. donovani promastigotes as
described previously [4]. Briefly, stationary-phase pro-
mastigotes, harvested after the third or fourth passage,
were washed three times in cold phosphate-buffered sa-
line, pH 7.2 (PBS), pelleted and resuspended at a con-
centration of 20 mg/mL in cold 5 mM Tris–HCl buffer
(pH 7.6). The suspension was centrifuged at 2,310 × g for
10 min to obtain crude ghost membrane pellet, resus-
pended in Tris–HCl buffer and sonicated for 3 min
using an ultrasound probe sonicator (Misonix, Farmingdale,
NY, USA). The suspension was clarified by centrifugation
(5,190 × g for 30 min), and supernatant containing the
LAg was stored at −70°C until use. The amount of pro-
tein obtained from a 1.0 g cell pellet was approximately
10 mg, as assayed by the method of Lowry et al. [45].
Imject alum purchased from Pierce (Pierce, Rockford, IL,
USA) and saponin purchased from Sigma-Aldrich were
used as adjuvants. Imject Alum was mixed with LAg di-
luted in PBS in a final ratio of 1:1. Saponin reconstituted
at 1 mg/ml in PBS was injected at 20 μg/dose with LAg.
Liposomes were prepared with egg lecithin (27 μmol),
cholesterol, and stearylamine (Sigma-Aldrich) at a molar
ratio of 7:2:2 as described previously [4]. Empty and LAg
containing liposomes were prepared by the dispersion of
lipid film in 1 ml PBS alone or containing 1 mg/ml LAg.
The amount of associated LAg per milligram of egg leci-
thin was 36 μg.
Immunization protocol and challenge infection
The experimental groups consisted of 4–6 weeks old
BALB/c mice. Mice (5 mice per group) were immunized
subcutaneously with 20 μg of LAg in PBS [4], either with
alum or saponin in a total volume of 200 μl. Mice were
boosted twice at 2 week intervals. Alternatively, mice
were immunized three times with empty liposomes or20 μg of LAg incorporated into liposomes, by intraperi-
toneal route, in a total volume of 200 μl at 2-week inter-
vals. Ten days after the last immunization the animals
were challenged with 2.5 × 107 freshly transformed sta-
tionary phase L. donovani promastigotes in 200 μl PBS
injected intravenously via the tail vein [4].
Evaluation of infection
Two and 4 months post L. donovani challenge infection,
cohorts of mice were monitored by the microscopic
examination of Giemsa stained impression smears of
liver and spleen. Parasite load was expressed in Leish-
man Donovan units, calculated by the following formula:
number of amastigotes per 1,000 cell nuclei × organ weight
(mg) [46].
Assessment of delayed type hypersensitivity response (DTH)
Delayed type hypersensitivity (DTH) responses were
evaluated by comparing the footpad swelling following
intradermal inoculation with 50 μL of LAg (800 mg/mL)
after 24 h relative to an alternative PBS control injection.
Swelling was measured using a constant pressure caliper
(Starrett Company, Athol, MA, USA) [4].
Determination of antibody responses by ELISA
Sera from individual mice in each experimental group
were collected before and after challenge with L. donovani.
96-well Microtiter plates (Maxisorp, Nunc, Roskilde,
Denmark) were coated overnight at 4°C with either
chicken egg albumin (OVA, Sigma–Aldrich, 25 μg/mL) or
LAg (25 μg/mL) diluted in 0.02 M phosphate buffer
(pH 7.5). Nonspecific binding was blocked with 1% bovine
serum albumin in PBS, and the plates were subsequently
washed with PBS containing 0.05% Tween 20. To mea-
sure total IgG, plates incubated overnight at 4°C with
mouse sera were incubated for 3 h with polyclonal goat
anti-mouse IgG conjugated to HRP (Sigma-Aldrich). To
measure IgG1, IgG2a and IgG2b, plates were incubated
overnight with monoclonal goat anti-mouse IgG1, IgG2a
and IgG2b (Sigma-Aldrich) followed by HRP conjugated
rabbit anti-goat IgG (Sigma-Aldrich) for 3 h. Wells were
washed with PBS and incubated for 30 min with o-
phenylenediamine dihydrochloride (0.8 mg/ml in 0.05 M
phosphate citrate buffer, pH 5.0, containing 0.04% H2O2).
Finally, absorbance was determined at 450 nm in an
ELISA plate reader (Thermo, Waltham, MA, USA).
Cytokine assays
Single cell suspensions of splenocytes were prepared in
RPMI 1640 supplemented with 10% FBS, l00 U/mL peni-
cillin G sodium, 100 μg/mL streptomycin sulfate and
50 μM β-mercaptoethanol (Sigma-Aldrich) (complete
medium). RBCs were lysed with 0.14 M Tris buffered
NH4Cl, and the remaining cells were washed twice with
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determined with a hemocytometer. Cells were cultured in
triplicate in a 96-well flat bottom plate (Nunc) at a density
of 2 × 105 cells/well in a final volume of 200 μL complete
medium and stimulated with LAg (10 μg/mL) in media
alone or in the presence of anti-CD4 and anti-CD8 mono-
clonal antibodies (1 μg/106 cells; BD Pharmingen, San
Diego, CA, USA). After 72 h incubation, culture superna-
tants were collected and the concentration of IL-12, IFN-
γ, IL-4 and IL-10 (BD Pharmingen) was quantitated by
ELISA in accordance with the manufacturer’s instructions
and as described previously [6].
Statistical analysis
One-way ANOVA statistical test was performed to as-
sess the differences among various groups. Multiple
comparisons Tukey-Kramer test was used to compare
the means of different experimental groups. A value of
P < 0.05 was considered to be significant.
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